166 related articles for article (PubMed ID: 36400552)
1. Chronic Migraine: Diagnosis and Management.
Kung D; Rodriguez G; Evans R
Neurol Clin; 2023 Feb; 41(1):141-159. PubMed ID: 36400552
[TBL] [Abstract][Full Text] [Related]
2. Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study.
Buse DC; Armand CE; Charleston L; Reed ML; Fanning KM; Adams AM; Lipton RB
Headache; 2021 Apr; 61(4):628-641. PubMed ID: 33797078
[TBL] [Abstract][Full Text] [Related]
3. Chronic migraine and medication overuse.
Diener HC; Rizzoli P
Handb Clin Neurol; 2023; 198():187-200. PubMed ID: 38043961
[TBL] [Abstract][Full Text] [Related]
4. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
[TBL] [Abstract][Full Text] [Related]
5. Chronic migraine treatment: from OnabotulinumtoxinA onwards.
Negro A; Curto M; Lionetto L; Giamberardino MA; Martelletti P
Expert Rev Neurother; 2016 Oct; 16(10):1217-27. PubMed ID: 27310178
[TBL] [Abstract][Full Text] [Related]
6. Real-life assessment of erenumab in refractory chronic migraine with medication overuse headache.
Pensato U; Baraldi C; Favoni V; Cainazzo MM; Torelli P; Querzani P; Pascazio A; Mascarella D; Matteo E; Quintana S; Asioli GM; Cortelli P; Pierangeli G; Guerzoni S; Cevoli S
Neurol Sci; 2022 Feb; 43(2):1273-1280. PubMed ID: 34224026
[TBL] [Abstract][Full Text] [Related]
7. A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience.
Negro A; Curto M; Lionetto L; Martelletti P
J Headache Pain; 2015; 17():1. PubMed ID: 26792662
[TBL] [Abstract][Full Text] [Related]
8. Identifying and managing refractory migraine: barriers and opportunities?
D'Antona L; Matharu M
J Headache Pain; 2019 Aug; 20(1):89. PubMed ID: 31443629
[TBL] [Abstract][Full Text] [Related]
9. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes.
Talbot J; Stuckey R; Crawford L; Weatherby S; Mullin S
J Headache Pain; 2021 Jan; 22(1):5. PubMed ID: 33421995
[TBL] [Abstract][Full Text] [Related]
10. Migraine preventive therapy: selection of appropriate patients and general principles of management.
D'Amico D; Lanteri-Minet M
Expert Rev Neurother; 2006 Aug; 6(8):1147-57. PubMed ID: 16893343
[TBL] [Abstract][Full Text] [Related]
11. The Diagnosis and Management of Chronic Migraine in Primary Care.
Becker WJ
Headache; 2017 Oct; 57(9):1471-1481. PubMed ID: 28548676
[TBL] [Abstract][Full Text] [Related]
12. Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA.
Torres-Ferrus M; Gallardo VJ; Alpuente A; Pozo-Rosich P
J Headache Pain; 2020 Jul; 21(1):88. PubMed ID: 32652924
[TBL] [Abstract][Full Text] [Related]
13. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
14. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.
Bendtsen L; Sacco S; Ashina M; Mitsikostas D; Ahmed F; Pozo-Rosich P; Martelletti P
J Headache Pain; 2018 Sep; 19(1):91. PubMed ID: 30259200
[TBL] [Abstract][Full Text] [Related]
15. Providing Care for Patients with Chronic Migraine: Diagnosis, Treatment, and Management.
Dougherty C; Silberstein SD
Pain Pract; 2015 Sep; 15(7):688-92. PubMed ID: 25271173
[TBL] [Abstract][Full Text] [Related]
16. Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.
Dodick DW; Loder EW; Manack Adams A; Buse DC; Fanning KM; Reed ML; Lipton RB
Headache; 2016 May; 56(5):821-834. PubMed ID: 27143127
[TBL] [Abstract][Full Text] [Related]
17. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review.
Martin V; Samaan KH; Aurora S; Pearlman EM; Zhou C; Li X; Pallay R
Adv Ther; 2020 May; 37(5):2034-2049. PubMed ID: 32319039
[TBL] [Abstract][Full Text] [Related]
19. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
[TBL] [Abstract][Full Text] [Related]
20. Medication-overuse headache.
Wakerley BR
Pract Neurol; 2019 Oct; 19(5):399-403. PubMed ID: 31273078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
